Chemerin is a recently identified adipokine suggested to play a role in obesity and its metabolic complications. The relationship between visceral obesity and serum chemerin levels in type 2 diabetes (T2DM) is unknown and may differ from that of subjects without diabetes. Therefore, we evaluated whether serum chemerin was associated with visceral abdominal obesity in patients with T2DM. A total of 218 Korean patients with T2DM were enrolled and metabolic parameters, abdominal visceral and subcutaneous fat areas, and serum chemerin levels were measured. Serum chemerin level showed positive correlation with fasting insulin, HOMA-IR, serum triglyceride, serum creatinine, urine albumin/ creatinine ratio, high-sensitivity C-reactive protein (hsCRP), fibrinogen, abdominal visceral fat area, visceral to subcutaneous fat area ratio, and negatively correlation with high density lipoprotein cholesterol and creatinine clearance (CCr) after adjusting for age, gender and body mass index. Multiple linear stepwise regression analysis showed that abdominal visceral fat area (β = 0.001, P < 0.001), serum triglyceride (β = 0.001, P < 0.001), CCr (β = -0.003, P = 0.001), hsCRP (β = 0.157, P = 0.001), fibrinogen (β = 0.001, P < 0.001), and BMI (β = 0.02, P = 0.008) independently affected log transformed serum chemerin levels. Higher serum chemerin level was associated with higher level of abdominal visceral fat area, serum triglyceride, hsCRP and fibrinogen and lower level of CCr in patients with T2DM. Serum chemerin may be used as a biomarker of visceral adiposity and chemerin may play a role in inflammation, decreased renal function, and increased cardiovascular risk in T2DM.
INTRODUCTION
In type 2 diabetes (T2DM), the pattern of adipose tissue distri bution is significantly different from individuals without diabe tes. Subjects with T2DM have more visceral adipose tissue and lesser subcutaneous adipose tissue than in healthy control sub jects (1) . Most studies have found that visceral adipose tissue is strongly related to insulin resistance in T2DM. Visceral fat ac cumulation has a significant negative impact on glycemic con trol through a decrease in peripheral insulin sensitivity and an enhancement of gluconeogenesis (2) and it is associated with the development of coronary heart disease (3).
T2DM seems to be closely related to the endocrine activity of adipose tissue. Adipose tissue is known to express and secrete a variety of adipokines, such as leptin, adiponectin, resistin, cheme rin, retinol binding protein4 (RBP4), omentin and adipocyte fatty acidbinding protein (AFABP). The release of adipokines by adipocytes can lead to a chronic inflammatory state that could play a central role in the development of insulin resistance and T2DM and is associated with the risk of cardiovascular disease (4) . However, among these adipokines, the potential role of che merin on T2DM and adiposity has not been fully examined and remains controversial.
Chemerin is a recently identified adipokine, which may par ticipate in the regulation of adipogenesis as well as the regula tion of inflammation. It may also play a role in insulin resistance, glucose and lipid metabolism (5) . Previous studies have shown that chemerin is associated with several aspects of the metabol ic syndrome (6) . Gene expression of chemerin is significantly higher in visceral adipose tissue compared with subcutaneous adipose tissue in normal glucose tolerance animals (6) . We pre viously showed a decrease in total body fat content and serum chemerin levels in overweight and obese patients with T2DM by an intensive lifestyle intervention (7) . Recently, a positive cor relation between visceral fat accumulation and serum chemer in levels in subjects without diabetes has been shown (8) . How ever, the relationship between serum chemerin levels and body fat composition, in particular visceral abdominal obesity in peo ple with T2DM has not been well studied and this relationship may be different from those without diabetes. Therefore, we in vestigated whether circulating chemerin levels might be associ ated with the degree of visceral obesity and other metabolic pa rameters in patients with T2DM.
MATERIALS AND METHODS

Study participants
In this study, 218 subjects with T2DM participated from the out patient clinic of Inha University Hospital Diabetes and Endocri nology Center, Incheon, Korea. Diabetes was defined according to the American Diabetes Association diagnostic criteria (9) . El igible participants were aged 2075 years with T2DM taking oral hypoglycemic agent, but not on insulin therapy. Participants who had a history of type 1 diabetes, active malignancy, infection and severe renal (serum creatinine level > 2 mg/dL) or hepatic disease (alanine aminotransferase or aspartate aminotransfer ase level greater than or equal to twofold higher than the upper normal limit), and patients taking an antiobesity drug or a thia zolidinedione were excluded.
Anthropometric measurement
Body weight, height, waist circumference (WC), and blood pres sure were measured. Body mass index (BMI) was calculated as weight (kg) divided by the square of height (m). WC was mea sured at the midpoint between the lower borders of the rib cage and the iliac crest. Blood pressure was measured after the sub ject has been in rest for at least 10 minutes in a sitting position.
Blood collection and biochemical analyses
Blood samples were collected after an overnight fast of at least 8 hours and stored at 80°C for subsequent assays. Serum glucose was measured by a hexokinase method and hemoglobin A1c (HbA1c) values were determined by highperformance liquid chromatography (HLC723G7, Tosoh, Tokyo, Japan). Insulin was measured by a radioimmunoassay (TFB, Tokyo, Japan). 
Measurement of abdominal adipose tissue
Intraabdominal adipose tissue area was measured by a com puted tomography (CT) scan (Lightspeed VCT 64 Rows, GE Healthcare, Waukesha, WI, USA). A 5 mm CT slice scan was ac quired at the L4L5 level with the subject supine. The adipose tissue area was determined electronically by setting the attenu ation values for a region of interest within a range of 250 to 50 Hounsfield unit (HU). The subcutaneous fat area was derived by subtracting the visceral fat area from the total abdominal fat area. The visceral to subcutaneous fat area ratio (V/S ratio) was also calculated.
Measurement of brachial ankle pulse wave velocity (baPWV)
baPWV was measured using model BP203RPE II volumeple thysmographic apparatus (Colin, Komaki, Japan). Each partici pant rested in the supine position for 10 minutes, and was ex amined with electrocardiographic electrodes placed on both wrists and cuffs wrapped around both brachia and ankles. Trans mission time was calculated as the time for the waveform to trav el between the right arm and both ankles, and the transmission distance between the right brachium and ankle was automati cally calculated based on the height of the participant. In the present study, the means of right and left baPWV were used for analysis.
Definition of diabetic retinopathy
Diabetic retinopathy was diagnosed by ophthalmologists ac cording to the international classification of diabetic retinopa thy as previously described (10) .
Statistical analysis
All calculations and statistical analyses were performed using the SPSS for Windows software (version 19.0, Chicago, IL, USA). Data are expressed as the mean ± SD. Baseline comparisons and characteristics according to presence of diabetic retinopa thy were assessed by ttest, Wilcoxon rank sum test and χ 2 test as appropriate. Partial Spearman's correlation analysis were used to examine the association between serum chemerin lev els and other metabolic variables. To establish the independent factors associated with chemerin levels, multiple linear stepwise regression analysis was used. Chemerin was log transformed and independent variables in the multiple stepwise regression analysis were age, gender, BMI, fasting insulin, HOMAIR, HDL cholesterol, triglyceride, serum creatinine, CCr, urine albumin/ http://dx.doi.org/10.3346/jkms.2016.31.6.924 cr ratio, hsCRP, fibrinogen, visceral fat area, and V/S ratio. Re sults were considered statistically significant if the P value was < 0.05.
Ethics statement
This study was approved by the institutional review board at Inha University Hospital (IRB 200667) and all participants pro vided written informed consent to participate in the study.
RESULTS
A total of 218 subjects (131 men and 87 women) participated in the study. Baseline clinical characteristics of this study subjects are summarized in Table 1 , and serum chemerin 80.3 ± 22.3 ng/mL. Serum chemerin level was positively correlated with BMI, WC, abdominal sub cutaneous fat area, abdominal visceral fat area, V/S ratio, blood pressure, fasting insulin, HOMAIR, triglyceride, urine albumin/ creatinine ratio, hsCRP, fibrinogen, and negatively correlated with HDLC. However, after adjusting for age, gender and BMI, serum chemerin level was positively correlated with fasting in sulin (r = 0.25, P < 0.001), HOMAIR (r = 0.19, P = 0.006), triglyc eride (r = 0.36, P < 0.001), serum creatinine (r = 0.21, P = 0.002), urine albumin/creatinine ratio (r = 0.25, P < 0.001), hsCRP (r = 0.31, P < 0.001), fibrinogen (r = 0.32, P < 0.001), abdominal vis ceral fat area (r = 0.28, P < 0.001), and V/S ratio (r = 0.30, P < 0.001), and negatively correlated with HDLC (r = 0.19, P = 0.005) and CCr (r = 0.18, P = 0.009) as shown in Table 2 and Fig. 1 . We also examined the association of serum chemerin levels with omen tin1 and lipocalin2, but no association was observed. Multiple linear stepwise regression analysis showed that abdominal vis ceral fat area (β = 0.001, P < 0.001), serum triglyceride (β = 0.001, hsCRP, high-sensitivity C-reactive protein; CCr, creatinine clearance; PWV, pulse wave velocity; V/S ratio, ratio of visceral to subcutaneous fat. , coefficient of determination. *Serum chemerin level was log-transformed. (Table 3) . When clinical characteristics were compared accord ing to the presence and absence of diabetic retinopathy, there were no significant differences in most parameters except for longer duration in those with diabetic retinopathy. Chemerin, omentin, lipocalin levels were not different according to the pres ence of diabetic retinopathy (Table 4) .
DISCUSSION
We report for the first time that serum chemerin levels are posi tively associated with abdominal visceral fat area using CT and fibrinogen was a definite factor associated with serum chemer in levels in patients with T2DM. In a previous study, chemerin level was significantly associated with visceral fat accumulation in subjects without diabetes (8) , and other studies reported that chemerin gene expression was significantly higher in visceral adipose tissue compared with subcutaneous adipose tissue in animals (5). However, the relationship between serum chemer in levels and abdominal fat area, especially subcutaneous and visceral fat in T2DM has not been well studied. In our previous study, a 12week intensive lifestyle intervention significantly decreased total body fat content and serum chemerin level (7) . In this study, baseline chemerin level was not associated with visceral abdominal fat and subcutaneous visceral fat. However, the number of participants was too small (n = 35) to explain the association between serum chemerin level and abdominal fat composition, and the participants were limited to only over weight and obese patients with T2DM. Since, there was a possi bility that serum chemerin concentration might be associated with abdominal fat area, especially visceral fat compartment in T2DM, we investigated this in a larger number of patients with T2DM and those with a broader range of BMI. Obesity, and in particular abdominal obesity, plays a major role in the pathogenesis of several metabolic and cardiovascu lar problems including T2DM, hypertension, atherosclerosis and coronary artery disease (11) . Especially, excess visceral adi posity is associated with impaired glucose tolerance, insulin re sistance, and atherogenic dyslipidemia (12) . In addition, viscer al fat has been associated with coronary stenosis, independent of traditional cardiovascular risk factors, in an asymptomatic population without a history of coronary artery disease (13) . Even within the normal range of BMI, accumulation of visceral fat remains to be an independent cardiovascular risk factor (14) . Visceral fat accumulation may also induce secretion of adipo cytokines. Oversecretion of proinflammatory adipocytokines, such as PAI1 or tumor necrosis factorα (TNFα) and hypose cretion of defensive adipocytokines, such as adiponectin, might be major mechanisms of insulin resistance and T2DM (15) . In recent years, several adipocytokines were newly discovered such as retinol binding protein4 (RBP4), vaspin, omentin, chemer in and adipocyte fatty acidbinding protein (AFABP). Among these adipocytokines, the effect of chemerin on the adipose tis sue and glucose metabolism remains controversial.
Chemerin is an adipokine which was recently found that has a role in adaptive and innate immunity, and regulates adipo cyte differentiation and metabolism by binding to and activat ing the seven transmembranespanning G proteincoupled re ceptor (GPCR), chemokinelike receptor 1 (CMKLR1) (5) . Se rum chemerin levels are increased in obesity (5), and the ex pression is especially higher in visceral adipose tissue compared with subcutaneous adipose tissue in normal glucose tolerance animals (6) . In addition, visceral fat mass quantified by mag netic resonance imaging was significantly associated with ge netic variations of RARRES2 which encodes chemerin in sub jects with an increased risk for T2DM (16) . WC is an easily check able method, however an imprecise measurement of abdomi nal adiposity because it is the sum of both subcutaneous and visceral adipose tissue compartments. Our results also found that WC was associated with chemerin level, but after adjusting for age, sex and BMI, the correlation of systemic chemerin level with WC was not significant. Therefore, assessment of visceral adipose tissue area requires imaging with radiographic tech niques such as CT or magnetic resonance imaging. In this re spect, measurement of chemerin levels which is positively as sociated with visceral obesity, may conveniently provide a more precise information about metabolic risk compared to BMI, WC or radiographic imaging such as CT.
Patients with diabetes have increased prevalence of hypert rigyceridemia. In diabetes, the impaired ability of insulin to in hibit the release of free fattyacid leads to hypertriglyceridemia (17) . There is a controversy whether hypertriglyceridemia is di rectly related with cardiovascular disease, however, some stud ies demonstrate that hypertriglyceridemia is associated with cardiovascular disease, especially in patients with insulin resis tance or in patient accompanying other type of dyslipidemias (e.g. increased small dense LDL cholesterol and low HDL cho lesterol) (17) . Recent studies have shown that serum chemerin levels are associated with metabolic risk factors including se rum triglyceride (1820). Takahashi et al. (21) showed that che merin levels were positively correlated with BMI, total choles terol, triglyceride levels and negatively correlated with HDLC in T2DM. Another study showed that chemerin levels were sig nificantly associated with BMI, triglyceride, creatinine, CCr af ter adjusting for age and gender in patients with T2DM (22) . Con sistent with previous studies, we found that multiple factors of metabolic syndrome were significantly associated with serum chemerin, especially serum triglyceride was independently af fecting serum chemerin levels.
In recent years, it has become clear that obesity is commonly associated with chronic lowgrade systemic inflammation and cardiovascular disease (23, 24) . Furthermore, visceral obesity rather than subcutaneous obesity is associated with elevated concentrations of inflammatory cytokines along with the incre ase in risk of cardiovascular disease and diabetes. Chemerin can contribute to initiation and progression of inflammation in the obese state by stimulating macrophage adhesion to extracellu lar matrix proteins and by promoting chemotaxis (25) . Chemer in synthesis is induced by the overexpression of proinflamma tory cytokines such as TNFα (26) in visceral adipose tissue, and chemerin participates in the recruitment and local activation of inflammatory cells in adipose tissue (27) . In addition, Weigert et al. (28) also identified that chemerin level was significantly higher in patients with elevated CRP in T2DM. Our study also identified that higher serum chemerin level was independently associated with higher hsCRP in T2DM. Furthermore, high che merin levels were associated with increasing risk of coronary artery disease and severity of atherosclerosis independently of other established cardiovascular risk factors (29) . In this respect, like other inflammatory factors such as hsCRP, TNFα and IL1 which promote atherogenesis, chemerin may be one of several factors that contribute to cardiovascular disease in T2DM. How ever, longterm prospective studies of cardiovascular outcome associated with serum chemerin level should be investigated.
Plasma fibrinogen is an acutephase protein, and is likely to increase with inflammation and has been identified as an inde pendent risk factor for cardiovascular disease and it is associat ed with traditional cardiovascular risk factors (30) . Plasma fi brinogen may also be increased in T2DM and be associated with a number of components of the metabolic syndrome (31) . These evidences indicate that hyperfibrinogenemia in T2DM could contribute to the excess cardiovascular morbidity and mortality. In the present study, for the first time, we identified that fibrinogen was a definite factor associated with serum che merin levels in T2DM. In accordance with the above findings, we suggest that serum chemerin levels in T2DM can serve as a predictor of inflammation and cardiovascular disease, like hsCRP and fibrinogen.
Recently, serum chemerin levels were reported to be signifi cantly higher in patients on chronic hemodialysis as compared with healthy subjects, suggesting that determinants of renal func tion are independently related to serum chemerin levels (32) . In addition, both CCr and serum creatinine were significantly associated with serum chemerin levels (22) . In accordance with these reports, our data showed that serum chemerin concen trations were significantly correlated with serum creatinine and CCr after adjusting age, sex, and BMI. Moreover, CCr was inde pendently associated with serum chemerin levels. These find ings indicate that elevated serum chemerin levels could be a mark er of low CCr associated with diabetic nephropathy.
This study has some limitations. First, the study population were Korean subjects with T2DM, therefore the relationship between circulating chemerin level and visceral adipose tissue should be studied further in other populations. Second, we only measured the total form of chemerin. Chemerin is secreted in an inactive form as prochemerin with significantly lower bio logical activity, and undergoes proteolytic cleavage on the C terminal by proteases such as neutrophil elastase, cathepsin G and plasmin to become a short form with varying biological ac tivity (6) . Adipocytes express the genes that encode for protease that activate chemerin, such as neutrophil elastase, mast cell tryptase, angiotensin converting enzyme, tPA, uPA, and cathep sin K (33) . Cterminaltruncated chemerin variants display ei ther more chemotactic or antiinflammatory effects, which is determined by the cleavage at distinct sites by different classes of proteases (34) . Therefore, additional studies are necessary to evaluate the change in chemerin subtypes and the significance of these changes In summary, abdominal visceral fat area, BMI, serum triglyc eride, hsCRP, fibrinogen, and CCr were independent factors af fecting serum chemerin levels in T2DM. Our data suggest that serum chemerin which is associated with many metabolic risk factors can be a predictor of the degree of visceral adiposity and may play an important role in inflammation, diabetic nephrop athy, and risk of cardiovascular disease in T2DM. Furthermore, the metabolic complications of obesity in T2DM are not fully predictable based on simple anthropometric measurements. Therefore, clinical utility of chemerin as a biomarker of visceral obesity in T2DM could be useful in early detection of these path ological states, and aid in finding candidates for more intensive lifestyle modification and therapy to prevent their unfavorable consequences.
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